Grail Launches Clinical Trial for Early Detection of Breast Cancer

Apr 20, 2017

NEW YORK (GenomeWeb) – Grail said today that it has begun a clinical trial, STRIVE, for its next-generation sequencing-based blood test for early-stage cancer detection. The firm will collaborate with the Mayo Clinic and Sutter Health to enroll up to 120,000 women at the time when they receive a mammogram. The goal will be to train and validate the test.

The STRIVE study will enroll women at the Mayo and throughout the Sutter Health system in Northern California.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Featured White Papers

Reliable Collection of High-Quality Samples for Gut Microbiome Studies

Can Saliva Replace Blood for DNA Collection and Analysis?

Best Practices for RNA Transcriptome Sequencing

Tissue Section Imaging

Jul

24

Featured Webinar

Identifying Inherited Risk Factors of Pancreatic Cancer Using Targeted Sequencing in a Large Cohort

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Aug

09

Featured Webinar

Analytical Utility of Mass-Spec Liquid Biopsy for NSCLC and Melanoma Samples

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.

Aug

14

Featured Webinar

From Panels to Exome – Assessing the Technical Performance of dsDNA Capture Probes for NGS Variant Detection

This webinar will explore advances in next-generation sequencing (NGS) library prep technologies and their relationship to the evolution of targeted gene panels.

Aug

15

Featured Webinar

The Cancer Avatar Project: Analyzing ctDNA to Monitor Treatment Response

This webinar will discuss the Cancer Avatar Project at the California Pacific Medical Center Research Institute (CPMCRI) and the efforts to overcome complexity of tumor profiling using the Accel-Amplicon sequencing workflow from Swift Biosciences.

Main menu